# Paula Rodríguez‐Otero

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paula-rodriguez-otero/

## Facts

| Field | Value |
| --- | --- |
| Citations | 13,122 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 57 |
| i10-index | 185 |
| Last Known Institution | Navarre Institute of Health Research |
| OpenAlex ID | https://openalex.org/A5080959881 |
| ORCID iD | 0000-0001-5236-7785 |
| Works | 684 |

## Researcher papers

- [Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study](https://scholariq.org/papers/belantamab-mafodotin-for-relapsed-or-refractory-multiple-myeloma-dreamm-2-a-two/)
- [Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma](https://scholariq.org/papers/ide-cel-or-standard-regimens-in-relapsed-and-refractory-multiple-myeloma/)
- [Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma](https://scholariq.org/papers/talquetamab-a-t-cell-redirecting-gprc5d-bispecific-antibody-for-multiple-myeloma/)
- [Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results](https://scholariq.org/papers/elranatamab-in-relapsed-or-refractory-multiple-myeloma-phase-2-magnetismm-3/)
- [Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://scholariq.org/papers/daratumumab-bortezomib-lenalidomide-and-dexamethasone-for-multiple-myeloma/)
- [Epigenetic Silencing of the Tumor Suppressor MicroRNA <i>Hsa-miR-124a</i> Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia](https://scholariq.org/papers/epigenetic-silencing-of-the-tumor-suppressor-microrna-i-hsa-mir-124a-i-regulates/)
- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)
- [LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma](https://scholariq.org/papers/locommotion-a-prospective-non-interventional-multinational-study-of-real-life/)
- [A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial](https://scholariq.org/papers/a-simplified-frailty-scale-predicts-outcomes-in-transplant-ineligible-patients/)
- [The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma](https://scholariq.org/papers/the-mechanism-of-action-of-the-anti-cd38-monoclonal-antibody-isatuximab-in/)
- [Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial](https://scholariq.org/papers/analysis-of-patient-reported-experiences-up-to-2-years-after-receiving/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

## Researcher university

- [Navarre Institute of Health Research](https://scholariq.org/institutions/navarre-institute-of-health-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.